Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

  title={Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.},
  author={Yvette L. Kasamon and Heather Jacene and Christopher D Gocke and L. Swinnen and Douglas E Gladstone and Brandy N. Perkins and Brian K Link and Leslie L Popplewell and Thomas Matthew Habermann and Joseph M. Herman and William Matsui and Richard M. Jones and Richard Frederick Ambinder},
  volume={119 18},
In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20(+) Hodgkin and Reed… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 21 extracted citations


Publications referenced by this paper.
Showing 1-10 of 22 references

Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma [abstract

  • A Younes, JM Connors, SI Park, NNH Hunder, SM. Ansell
  • Blood (ASH Annual Meeting Abstracts)
  • 2011

High dose cyclophosphamide (Cy), rituximab, and a cancer vaccine for relapsed classical Hodgkin’s lymphoma (cHL) [abstract

  • YL Kasamon, RJ Jones, HI Levitsky
  • Blood (ASH Annual Meeting Abstracts)
  • 2010

Similar Papers

Loading similar papers…